跳至主要内容
临床试验/DRKS00017242
DRKS00017242已完成未知

MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer - FOKATU-Pilot

niversitätsklinikum Dresden, Klinik und Poliklinik für Strahlentherapie und Radioonkologie0 个研究点目标入组 6 人开始时间: 2019年5月9日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
65 Years 至 80 Years(—)
性别
Male

入选标准

  • locally limited unilateral, histologically confirmed prostate carcinoma
  • - male patients aged > 65 years < 80 years
  • - patients in good general condition (ECOG 0-1)
  • - histologically confirmed adenocarcinoma of the prostate (targeted MR-fused biopsy combined with systematic biopsy). Histologic confirmation should be > 6 weeks and < 4 months prior to the planned therapy and should be performed by MR-fused biopsy.
  • - localized unilateral prostate carcinoma with visible lesion in baseline MRI.
  • - maximum stage cT2a, Gleason 3+3=6 with maximum 4 affected cylinders or maximum stage cT2a with Gleason 3+4=7 with maximum 2 affected cylinders and maximum 50% of the punch cylinder surface affected.
  • - initial PSA value <15 ng/ml
  • - prostate volume < 90 ml
  • - general anesthetic ability (ASA category <3)
  • - MRI capability (see exclusion criteria)
  • - ability to consent and written consent of the patient

排除标准

  • - Bilateral infestation of the prostate gland
  • - capsule transgression, sphincter infiltration, seminal vesicle infiltration, lymph node infestation, metastases
  • - distance of tumor in baseline MRI more than 30 mm from urethra or within 3 mm around urethra, or in apex within 3 mm from sphincter
  • - Previous transurethral resections of the prostate (TURP-P) or other prostate surgical procedures
  • - Prostate calcifications (> 1 cm) within the sector to be treated (detected in TRUS, possibly in screening CT)
  • - Cysts on the prostate capsule within the area to be treated (baseline MRI)
  • - Clinically relevant prostatitis requiring treatment in the last 6 months prior to planned therapy
  • - Previous operations of the rectum or pelvis
  • - Chronic inflammatory bowel disease or other chronic diseases affecting the rectum, including fistulas and anal stenosis.
  • - Z.n. Radiotherapy of the pelvis
  • - Bladder or urethral dysfunction incl. urethralastricture, bladder diverticula, urethroplasty, fistulas etc.
  • - Patients with an artificial bladder sphincter or penis implant
  • - Severe neurogenic bladder dysfunction
  • - Symptomatic prostate hyperplasia with significant residual urine formation
  • - Untreated bladder stones
  • - Acute urinary retention within the last 12 months
  • - Acute untreated urinary tract infection
  • - Active untreated macrohaematuria
  • - Contraindications for MRT (cardiac pacemakers, defibrillators, non-mR-compatible endoprostheses, insulin pumps, grenade splinters, magnetic or electrically conductive implants, etc.)
  • - Contraindications for the insertion of a suprapubic bladder catheter: pre-surgery in the pelvis, scars in the area of the lower abdomen, vascular Y-prostheses, etc.
  • - Incompatibility/allergy to gadolinium (MRT contrast medium)
  • - Participation of the patient in another clinical trial if this requires further experimental therapy or if the therapies/study protocols are mutually exclusive.
  • - addiction or other illnesses which do not allow the person concerned to assess the nature and extent as well as possible consequences of the clinical trial
  • - Absence of written declaration of consent

研究者

发起方
niversitätsklinikum Dresden, Klinik und Poliklinik für Strahlentherapie und Radioonkologie

相似试验